July 16th, 2013
Follow-up after Barrett esophagus ablation: How do you do it, and when do you stop (if ever)?
We have shifted the paradigm of treating neoplastic Barrett esophagus (BE) away from a choice between intensive surveillance or surgery and towards endoscopic ablation. In the last 5 years, I have done hundreds of BE ablations using radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR), and many thousands have been performed worldwide. However, on post-ablation surveillance, evidence is lacking on whether and when patients can be cut loose. Moreover, I am beginning to see patients who were believed to be cured after ablation (no signs of BE or neoplasia during years of surveillance) showing up with adenocarcinoma in the distal esophagus 4 or more years later.
Until now, I have been telling my patients that once they are BE- and dysplasia-free, I want them to undergo surveillance every 4 months for 1 year, then every 6 months for 1 year, then yearly for a couple of years, and then every other year if things remain stable.
But given the uncertainties I’ve outlined above, I am interested in discussing your practices and recommendations for surveillance after ablation for BE.
On that note, what would your approach be in the following cases?
1) If a patient with high-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
2) If a patient with low-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
3) If a patient with NO dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
4) Do you ever tell patients that they are cured and no longer need surveillance (e.g., after 5 years, after 10 years, etc.)?
5) If a patient with dysplasia has their neoplastic BE completely ablated (no dysplasia but residual BE), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
Please join the discussion to shed some light on this issue.
Categories: Barrett esophagus, cancer surveillance, Patient care, practice environment, Uncategorized
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
Pages
Archives
- October 2014
- August 2014
- July 2014
- June 2014
- March 2014
- January 2014
- December 2013
- November 2013
- September 2013
- August 2013
- July 2013
- June 2013
- April 2013
- February 2013
- December 2012
- November 2012
- October 2012
- August 2012
- July 2012
- April 2012
- February 2012
- January 2012
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- October 2010
- August 2010
- July 2010
- March 2010
- February 2010
- January 2010
- December 2009
- July 2009
- June 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Categories
- Barrett esophagus (1)
- cancer surveillance (4)
- colonoscopy (4)
- drugs (1)
- Endoscopy (23)
- eosinophilic esophagitis (1)
- gastric acid suppression (1)
- Health policy (3)
- Hepatology (3)
- Medical education (1)
- pathology (1)
- Patient care (28)
- polypectomy (2)
- practice environment (3)
- Probiotic therapy (1)
- Ulcer (1)
- Uncategorized (30)
-
Tag Cloud
- Ambulatory endoscopy center antiretroviral therapy Barrett esophagus boceprevir bowel preparation CMS colitis colonoscopy colorectal cancer screening CT colonography DDW drug interactions efavirenz endoscopist Endoscopy gastroenterology GI bleeding hepatitis HIV IBS Irritable Bowel Syndrome Medicare midazolam nurse Plavix PPIs primary care probiotics ritonavir Screening colonoscopy sedation sigmoidoscopy telaprevir training virtual colonoscopy
